Nanotechnology in dermatology

Anais Brasileiros de Dermatologia

Volumn 89, Issue 1, 2014, Pages 126-136

  Antonio, João Roberto ^a   Antônio, Carlos Roberto ^a   Cardeal, Izabela Lídia Soares ^a   Ballavenuto, Julia Maria Avelino ^b   Oliveira, João Rodrigo ^b  

^a HOSPITAL DE BASE   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

Drug delivery systems; Drug interchangeability; Nanoparticles; Nanostructures

Indexed keywords

ACTSORB SILVER 220; CLOTRIMAZOLE; CORTICOSTEROID; COSMETIC; CYCLODEXTRIN; CYCLOSPORIN A; DENDRIMER; FINASTERIDE; FULLERENE; LIPOSOME; METHOTREXATE; MINOXIDIL; NANOCHLOREX; NANOPARTICLE; NANOSPHERE; NEOBENZ MICRO WASH PLUS PACK; NEOBENZMICRO; NIOSOME; PSORALEN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; VIROSOME;

ALOPECIA; DERMATOLOGY; DRUG TRANSPORT; ENCAPSULATION; FUNDING; GENE THERAPY; HAIR FOLLICLE; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MELANOMA; MICROCAPSULE; NANOTECHNOLOGY; NONHUMAN; PHOTOTOXICITY; QUESTIONNAIRE; REVIEW; RISK; SCALP DISEASE; SEBACEOUS GLAND DISEASE; SKIN DISEASE; SKIN PENETRATION; TUMOR GROWTH;

DERMATOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; SKIN DISEASES;

EID: 84896058421     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20142228     Document Type: Review

References (139)

1. Bhushan B. Springer handbook of nanotecnology. 2nd ed. Heidelberg, Germany: Springer-Verlag; 2007.
2. Nasir A. Nanodermatology: a glimpse of caution just beyond the horizon - part II. Skin Therapy Lett. 2010;15:4-7.
3. Drexler KE. Machine-phase nanotechnology. Sci Am. 2001;285:74-5.
4. Drexler KE. Nanosystems: molecular machinery, manufacturing, and computation. New York: John Wiley & Sons, Inc; 1992.
5. Hall JS. Nanofuture: what's next for nanotechnology. New York: Prometheus Books; 2005.
6. Nasir A. The Future of Nanotecnology in Dermatology. US Dermatology. 2008;3:9-13.
7. Nasir A. Nanotechnology and dermatology: part I-potential of nanotechnology. Clin Dermatol. 2010;28:458-66.
8. Saraceno R, Chiricozzi A, Gabellini M, Chimenti S. Emerging applications of nano-medicine in dermatology. Skin Res Technol. 2013;19:e13-9.
9. Friedman A, Nasir A. Nanotechnology and dermatology education in the United States: data from a pilot survey. J Drugs Dermatol. 2011;10:1037-41.
10. Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A. Nanoparticles in dermatology. Arch Dermatol Res. 2011;303:533-50.
11. Jung S, Otberg N, Thiede G, Richter H, Sterry W, Panzner S, et al. Innovative lipo-somes as a transfollicular drug delivery system: penetration into porcine hair follicles. J Invest Dermatol. 2006;126:1728-32
12. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60:915-28.
13. de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine. 2009;27:947-55.
14. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007;18:537-45
15. Mahe B, Vogt A, Liard C, Duffy D, Abadie V, Bonduelle O, et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol. 2009;129:1156-64.
16. Chirico F, Fumelli C, Marconi A, Tinari A, Straface E, Malorni W, et al. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp Dermatol. 2007;16:429-36.
17. Kato S, Taira H, Aoshima H, Saitoh Y, Miwa N. Clinical evaluation of fullerene-C60 dissolved in squalane for antiwrinkle cosmetics. J Nanosci Nanotechnol. 2010;10:6769-74.
18. Villalonga-Barber C, Micha-Screttas M, Steele BR, Georgopoulos A, Demetzos C. Dendrimers as biopharmaceuticals: synthesis and properties. Curr Top Med Chem. 2008;8:1294-309.
19. Venuganti VV, Perumal O P. Poly(amidoamine) dendrimers as skin penetration enhancers: Influence of charge, generation, and concentration. J Pharm Sci. 2009;98:2345-56.
20. Kristl J, Teskac K, Grabnar PA. Current view on nanosized solid lipid carriers for drug delivery to the skin. J Biomed Nanotechnol. 2010;6:529-42.
21. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)-structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15:393-402.
22. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-43.
23. Walther C, Meyer K, Rennert R, Neundorf I. Quantum dot-carrier peptide conjugates suitable for imaging and delivery applications. Bioconjug Chem. 2008;19:2346-56.
24. Zhou M, Nakatani E, Gronenberg LS, Tokimoto T, Wirth MJ, Hruby VJ, et al. Peptidelabeled quantum dots for imaging GPCRs in whole cells and as single molecules. Bioconjug Chem. 2007;18:323-32.
25. Lourenço VA. Desenvolvimento e avaliação de micropartículas de quitosana para a veiculação de dimetilaminoetanol (DMAE) na pele [dissertação]. Ribeirão Preto (SP): Universidade de São Paulo; 2006.117 p.
26. Gupchup G V, Zatz J. Target delivery to pilosebaceous structures. Cosmet Toiler. 1997;112:79-88.
27. Abraham MH, Chadha HS, Mitchell RC. The factors that influence skin permeation os solutes. J Pharm Pharmacol. 1955;47:8-16.
28. Cevc G, Blume G, Schätzlein A, Gebauer D, Paul A. The skin: a pathway for systemic treatment with patches and lipid based carriers. Adv Drug Deliv Rev 1996;18:349-78.
29. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101-14.
30. Vogt A, Mandt N, Lademann J, Schaefer H, Blume-Peytavi U. Follicular targeting-a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc. 2005 Dec;10(3):252-5.
31. Kumar MN, Kumar N. Polymeric Controlled Drug-Delivery Systens: Perspective Issues and Opportunities. Drug Dev Ind Pharm. 2001 Jan;27(1):1-30.
32. Embil K, Nacht S. The microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13:575-88.
33. Rogers K. Controled release technology and delivery systems. Cosmet Toiler. 1999;114:53-60.
34. Nacht S. Encapsulation and other topical delivery systems: a review of the state-of-the-art for controlled topical delivery. Cosmet Toiler. 1995;110:25-30.
35. Tran MA, Watts RJ, Robertson G P. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009;22:388-99.
36. Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targenting of terminal hair follicles. J Invest Dermatol. 2004;123:168-76.
37. Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. Site-specific drug delivery to pilosebaceous strutures using polymeric microspheres. Pharm Res. 1993;10:1738-44.
38. Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targenting to the upper skin. Eur J Pharm Biopharm. 2000;49:211-8.
39. Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancemente of topical delivery from biodegradable nanoparticles. Pharm Res. 2004;21:1818-25.
40. Freitas MN, Marchetti JM. Nimesulide PLA microspheres as a potencial sustained release system for the treatment of inflammatory diseases. Int J Pharm. 2005;295:201-11.
41. Couvrer P, Covarraze G, Devissaguet J P, Puisiex F. Nanoparticles: Preparation and Caracterization. Microencapsulation Methods and Industrial Applications. New York: Marcel Dekker, Inc.; 1996. p.183-211.
42. Finch CA. Microencapsulation. In: Elvers, B; Hawkins, S; Schulza, G. Encyclopedia of Industrial Chemitry. 5th ed. Neihein: VCH Verlagsgesell-sehaft; 1990. p.575-88.
43. Wang SQ, Tooley IR. Photoprotection in the era of nanotechnology. Semin Cutan Med Surg. 2011;30:210-3.
44. Schilling K, Bradford B, Castelli D, Dufour E, Nash J F, Pape W, et al. Human safety review of nano titanium dioxide and zinc oxide. Photochem Photobiol Sci. 2010;9:495-509.
45. Tan MH, Commens CA, Burnett L, Snitch PJ. A pilot study on the percutaneous absorption of microfine titanium dioxide from sunscreens. Australas J Dermatol. 1996;37:185-7.
46. Dussert AS, Gooris E, Hemmerle J. Characterization of the mineral content of a physical sunscreen emulsion and its distribution onto human stratum corneum. Int J Cosmet Sci. 1997;19:119-29.
47. Lademann J, Weigmann H, Rickmeyer C, Barthelmes H, Schaefer H, Mueller G, et al. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol. 1999;12:247-56.
48. Schulz J, Hohenberg H, Pflücker F, Gärtner E, Will T, Pfeiffer S, et al. Distribution of sunscreens on skin. Adv Drug Deliv Rev. 2002;54 Suppl 1:S157-63.
49. Gontier E, Ynsa M-D, Biro T, Hunyadij J, Kiss B, Gáspár K, et al. Is there penetration of titania nanoparticles in sunscreens through skin? A comparative electron and ion microscopy study. Nanotoxicology. 2008; 2:218-231.
50. Cross SE, Innes B, Roberts MS, Tsuzuki T, Robertson TA, McCormick P. Human skin penetration of sunscreen nanoparticles: In-vitro assessment of a novel micro-nized zinc oxide formulation. Skin Pharmacol Physiol. 2007;20:148-54.
51. Mavon A, Miquel C, Lejeune O, Payre B, Moretto P. In vitro percutaneous absorption and in vivo stratum corneum distribution of an organic and a mineral sunscreen. Skin Pharmacol Physiol. 2007;20:10-20.
52. Pinheiro T, Pallon J, Alves LC, Veríssimo A, Filipe P, Silva JN. The influence of cor-neocyte structure on the interpretation of permeation profiles of nanoparticles across skin. Nucl Instrum Methods Phys Res B. 2007;260:119-23.
53. Zvyagin AV, Zhao X, Gierden A, Sanchez W, Ross JA, Roberts MS. Imaging of zinc oxide nanoparticle penetration in human skin in vitro and in vivo. J Biomed Opt. 2008;13:064031.
54. Sadrieh N, Wokovich AM, Gopee N V, Zheng J, Haines D, Parmiter D, et al. Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles. Toxicol Sci. 2010;115:156-66.
55. Filipe P, Silva JN, Silva R, Cirne de Castro JL, Marques Gomes M, Alves LC, et al. Stratum corneum is an effective barrier to TiO2 and ZnO nanoparticle percutaneous absorption. Skin Pharmacol Physiol. 2009;22:266-75
56. Durand L, Habran N, Henschel V, Amighi K. In vitro evaluation of the cutaneous penetration of sprayable sunscreen emulsions with high concentrations of UV filters. Int J Cosmet Sci. 2009;31:279-92
57. Johnston HJ, Hutchison GR, Christensen FM, Peters S, Hankin S, Stone V. Identification of the mechanisms that drive the toxicity of TiO2 particulates: The contribution of physicochemical characteristics. Part Fibre Toxicol. 2009;6:33.
58. Hirakawa K, Mori M, Yoshida M, Oikawa S, Kawanishi S. Photo-irradiated titanium dioxide catalyzes site specific DNA damage via generation of hydrogen peroxide. Free Radic Res. 2004;38:439-47.
59. Wamer WG, Yin JJ, Wei RR. Oxidative damage to nucleic acids photosensitized by titanium dioxide. Free Radic Biol Med. 1997;23:851-8.
60. Nakagawa Y, Wakuri S, Sakamoto K, Tanaka N. The photogenotoxicity of titanium dioxide particles. Mutat Res. 1997;394:125-32.
61. Hidaka H, Kobayashi H, Koike T, Sato T, Serpone N. DNA damage photoinduced by cosmetic pigments and sunscreen agents under solar exposure and artificial UV illumination. J Oleo Sci. 2006; 55:249-61.
62. Morganti P. Use and potential of nanotechnology in cosmetic dermatology. Clin Cosmet Investig Dermatol. 2010;3:5-13.
63. Souto EB, Müller RH. Challenging Cosmetics-Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC). In: Wiechers JW, editor. Science and Application of Skin Delivery Systems. Coral Stream: Allured Publ.Co; 2008. p.227-250.
64. Abramovits W, Granowski P, Arrazola P. Applications of Nanomedicine in Dermatology: use of nanoparticles in various therapies and imaging. J Cosmet Dermatol. 2010;9:154-9
65. Vinetsky Y, Magdassi S. Microcapsules in cosmetics. In: Magdassi S, Touitou E. Novel Cosmetic Delivery Systems. New York: Marcel Dekker Inc; 1999. p.295-313.
66. Muzzarelli RAA. Chitin and its derivates: new trends off applied research. Carbohydr Polym. 1993;3:53-75.
67. Percot A, Viton C, Domard A. Optimization of chitin extraction from shrimp shell. Biomacromolecules. 2003;4:12-8.
68. Muzzarelli RAA, Mattioli-Belmonte M, Pugnaloni A, Biagini G. Biochemistry, histology and clinical uses of chitins and chitosans in wound healing. In: Jollés P, Muzzarelli RAA, editors. Chitin and Chitinases. Swizterland: Birkhaüser Verlag; 1999. p.251-264.
69. Muzzarelli RAA, Muzzarelli C. Chitin nanofibrils. In: Dutta PK, editor. Chitin and Chitosan: Research Opportunities and Challenges. Contai: SSM International Publication; 2005. p.129-46.
70. Mattioli-Belmonte M, Zizzi Z, Lucarini G, Giantomassi F, Biagini G, Tucci G, et al. Chitin nanofibrils linked to chitosan glycolate as spray, gel and gauze preparations for wound repair. J Bioact Compat Polym. 2007;22:525-538.
71. Mezzana P. Clinical efficacy of a new chitin-nanofibrils based gel in wound healing. Acta Chir Plast. 2008;50:81-4.
72. Lademann J, Richter H, Golz K, Zastrow L, Sterry W, Patzelt A. Influence of micro-particles on the homogeneity of distribution of topically applied substances. Skin Pharmacol Physiol. 2008;21:274-82
73. de Fine Olivarius F, Hansen AB, Karlsmark T, Wulf HC. Water protective effect of barrier creams and moisturizing creams: a new in vivo test method. Contact Dermatitis. 1996;35:219-25.
74. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target. 2002;10:489-95.
75. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, Yang Y, et al. Podophyllotoxin-loa-ded solid lipid nanoparticles for epidermal targeting. J Control Release. 2006;110:296-306.
76. Erdogan M, Wright JR Jr, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol. 2002;146:964-7.
77. Egbaria K, Ramachandran C, Weiner N. Topical application of liposomally entrapped cyclosporin evaluated by in vitro diffusion studies with human skin. Skin Pharmacol. 1991;4:21-8.
78. Ali M F, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit. 2008;14:P 166-174.
79. Fang J Y, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical pso-ralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70:633-40.
80. Saraswat A, Agarwal R, Katare O P, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat. 2007;18:40-5.
81. Lboutounne H, Chaulet J F, Ploton C, Falson F, Pirot F. Sustained ex vivo skin antiseptic activity of chlorhexidine in poly(epsilon-caprolactone) nanocapsule encapsulated form and as a digluconate. J Control Release. 2002;82:319-34.
82. Lboutounne H, Faivre V, Falson F, Pirot F. Characterization of transport of chlorhe-xidine-loaded nanocapsules through hairless and wistar rat skin. Skin Pharmacol Physiol. 2004;17:176-82.
83. Harbarth S, Pittet D, Grady L, Zawacki A, Potter-Bynoe G, Samore MH, et al. Interventional study to evaluate the impact of an alcohol-based hand gel in improving hand hygiene compliance. Pediatr Infect Dis J. 2002;21:489-95.
84. Nhung D T, Freydiere AM, Constant H, Falson F, Pirot F. Sustained antibacterial effect of a hand rub gel incorporating chlorhexdine-loaded nanocapsules (Nanochlorex). Int J Pharm. 2007;334:166-72.
85. Tsuang YH, Sun JS, Huang YC, Lu CH, Chang WH, Wang CC. Studies of photokil-ling of bacteria using titanium dioxide nanoparticles. Artif Organs. 2008;32:167-74.
86. Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett. 2008;176(:1-12.
87. Pitsillides CM, Joe EK, Wei X, Anderson RR, Lin C P. Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys J. 2003;84:4023-32.
88. Dickerson EB, Dreaden EC, Huang X, El-Sayed IH, Chu H, Pushpanketh S, et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett. 2008;269:57-66.
89. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006;239:129-35.
90. Lu W, Xiong C, Zhang G, Huang Q, Zhang R, Zhang JZ, et al. Targeted photother-mal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer Res. 2009;15:876-86.
91. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-57
92. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60:1627-37.
93. Rancan F, Helmreich M, Mölich A, Ermilov EA, Jux N, Röder B, et al. Synthesis and in vitro testing of a pyropheophorbide-a-fullerene hexakis adduct immunoconjuga-te for photodynamic therapy. Bioconjug Chem. 2007;18:1078-86.
94. Khdair A, Chen D, Patil Y, Ma L, Dou Q P, Shekhar M P, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010;141:137-44.
95. Taglietti M, Hawkins CN, Rao J. Novel topical drug delivery systems and their potential use in acne vulgaris. Skin Therapy Lett. 2008;13:6-8.
96. Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol. 2000;5:455-64.
97. Queille-Roussel C, Poncet M, Mesaros S, Clucas A, Baker M, Soloff AM. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel. Clin Ther. 2001;23:205-12.
98. Castro GA, Coelho AL, Oliveira CA, Mahecha GA, Oréfice RL, Ferreira LA. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm. 2009;381:77-83.
99. Castro GA, Oliveira CA, Mahecha GA, Ferreira LA. Comedolytic effect and reduced skin irritation of a new formulation of all-trans retinoic acid-loaded solid lipid nano-particles for topical treatment of acne. Arch Dermatol Res. 2011;303:513-20.
100. Bernard E, Dubois JL, Wepierre J. Importance of sebaceous glands in cutaneous penetration of an antiandrogen: target effect of liposomes. J Pharm Sci. 1997;86:573-8.
101. Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, et al. RU 58841-myristate-prodrug development for topical treatment of acne and androge-nética alopecia. Pharmazie. 2005;60:8-12.
102. Bikowski J, Del Rosso JQ. Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol. 2008;7:590-5.
103. Tsujimoto H, Hara K, Tsukada Y, Huang CC, Kawashima Y, Arakaki M, et al. Evaluation of the permeability of hair growing ingredient encapsulated PLGA nanospheres to hair follicles and their hair growing effects. Bioorg Med Chem Lett. 2007;17:4771-7
104. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release. 2004;97:477-84.
105. Jain B, Singh B, Katare O P, Vyas S.P. Development and characterization of minoxi-dil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res. 2010;20:105-14.
106. Kumar R, Singh B, Bakshi G, Katare O P. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation. Pharm Dev Technol. 2007;12:591-601.
107. Vogt A, Combadiere B, Hadam S, Stieler KM, Lademann J, Schaefer H, 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcuta-neous application on human skin. J Invest Dermatol. 2006;126:1316-22.
108. Nakamura M, Jo J, Tabata Y, Ishikawa O. Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (alopecia areata) in a C3H/HeJ mouse model. Am J Pathol. 2008;172:650-8.
109. Ahmed, N et al. Theranostic applications of nanoparticles in câncer. Drug Discov Today. 2012;17:928-34.
110. Persidis A. Cancer multidrug resistance. Nat Biotechnol.1999;17:94-5.
111. Parveen S, Sahoo SK. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet. 2006;45:965-88.
112. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3:20-31.
113. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-35.
114. Plosker GL, Figgitt D P. Rituximab: a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803-43.
115. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
116. Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 1999;38:535-47.
117. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117-27.
118. Guerry D 4th, Synnestvedt M, Elder DE, Schultz D. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol. 1993;100:342S-345S.
119. Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007;7:833-7.
120. Solanki A, Kim JD, Lee KB. Nanotechnology for regenerative medicine: nanomate-rials for stem cells imaging. Nanomedicine (Lond). 2008;3:567-78.
121. Li Z, Chen H, Bao H. Gao M. One-pot reaction to synthesize water-soluble magnetite nanocrystals. Chem Mater. 2004;16:1391-3.
122. Souza KC, Salazar-Alvarez G, Ardisson JD, Macedo WA, Sousa EM. Mesoporous silica-magnetite nanocomposite synthesized by using a neutral surfactant. Nanotechnology. 2008;19:185603.
123. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta. 2005;358:37-54.
124. Olafsson R, Bauer DR, Montilla LG, Witte RS. Realtime, contrast enhanced photoa-coustic imaging of cancer in a mouse window chamber. Opt Express. 2010;18:18625-32.
125. Hia J, Nasir A. Photonanodermatology: the interface of photobiology, dermatology and nanotechnology. Photodermatol Photoimmunol Photomed. 2011;27:2-9.
126. Eden JG, Park S-J, Ostrom N P, Chen K-F. Recent advances in microcavity plasma devices and arrays: a versatile photonic platform J Phys D Appl Phys. 2005;38:1644-8.
127. Lim JK, Majetich SA, Tilton RD. Stabilization of superparamagnetic iron oxide core-gold shell nanoparticles in high ionic strength media. Langmuir. 2009;25:13384-93.
128. Kamei K, Mukai Y, Kojima H, Yoshikawa T, Yoshikawa M, Kiyohara G, et al. Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery. Biomaterials. 2009;30:1809-14.
129. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 2005;21:8858-64.
130. Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, Drug-loaded superparamagne-tic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl. 2008;47:5362-5.
131. Melancon M P, Lu W, Zhong M, Zhou M, Liang G, Elliott AM, et al. Targeted multifunctional gold-based nanoshells for magnetic resonance-guided laser ablation of head and neck cancer. Biomaterials. 2011;32:7600-8.
132. Yang X, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Steeber DA, et al. Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer therapy and MR imaging. Biomaterials. 2010;31:9065-73.
133. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today. 2012;17:1044-52.
134. Crosera M, Bovenzi M, Maina G, Adami G, Zanette C, Florio C, et al. Nanoparticle dermalabsorption and toxicity: a review of the literature. Int Arch Occup Environ Health. 2009;82:1043-55.
135. Nel A, Xia T, Meng H, Wang X, Lin S, Ji Z, et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput. Acc Chem Res. 2013;46:607-21.
136. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311:622-7.
137. Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nanobio interface. Nat Mater. 2009;8:543-57.
138. George S, Pokhrel S, Xia T, Gilbert B, Ji Z, Schowalter M.A et al. Use of a rapid cytotoxicity screening approach to engineer a safer zinc oxide nanoparticle through iron doping. ACS Nano. 2010;4:15-29.
139. Mura S, Couvreur P. Nanotheranostics for personalized medicine, Adv Drug Deliv Rev. 2012;64:1394-416.